Trial reportThe Journal of clinical investigation2013
B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells.
Trial report in The Journal of clinical investigation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
99 citing papers in PubMed, 1 synthesis or guideline pooled it, 187 citations in OpenAlex.
- Immune thrombocytopenia in patients with systemic lupus erythematosus.Clinical rheumatology · 2025Pooled it
- Safety and efficacy of daratumumab in immune thrombocytopenia.Blood advances · 2026Trial
- B cell-activating factor modulates the factor VIII immune response in hemophilia A.The Journal of clinical investigation · 2021Trial
- Trial
- Targeting B-Cell-Activating Factor and Its Receptor in Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia.American journal of hematology · 2026Review
- Longitudinal Anti-HBs Monitoring and Seroprotection Patterns in Rituximab-Treated Patients with Pemphigus Vulgaris: A Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- Epigenetic regulation of B cell tolerance and dysfunction in autoimmune disease.Nature reviews. Immunology · 2026Review
- Synergistic Interaction Between MALAT1/miR-30b-5p/BAFF Axis and Inflammatory Cytokines Underlies Rituximab-Refractory NMOSD.CNS neuroscience & therapeutics · 2026Article
- Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial.EClinicalMedicine · 2026Article
- Identification and characterization of bone marrow plasma cells producing IFN-γ-neutralizing autoantibodies in adult-onset immunodeficiency.Cell reports. Medicine · 2026Article
- Daratumumab for relapsed refractory immune thrombotic thrombocytopenic purpura: initial response and long-term follow-up.Research and practice in thrombosis and haemostasis · 2026Article
- Chimeric antigen receptor T-cell therapy for rheumatic diseases: from B-cell depletion to immune reset and beyond.Frontiers in immunology · 2026Review
- Unveiling an Immunological Mystery: Deciphering the Durability Divide in Vaccine-Elicited Antibody Responses.Current HIV research · 2026Review
- Additive Obinutuzumab Achieves High Remission Rates in Rituximab-Refractory Membranous Nephropathy.American journal of nephrology · 2026Article
- How we manage immune-mediated thrombotic thrombocytopenic purpura after rituximab failure or intolerance.British journal of haematology · 2025Review
- Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab era.Blood advances · 2025Article
- Immune thrombocytopenia in adolescents and young adults.Frontiers in medicine · 2025Review
- Daratumumab and Romiplostim Combined Therapy for a Long-Standing Refractory Primary Immune Thrombocytopenia - Case Report.ImmunoTargets and therapy · 2025Article
- Contribution of long-lived plasma cells to antibody-mediated allograft rejection.Clinical transplantation and research · 2024Review
- BAFF-associated granulomatous lung disease in a patient with GATA2 deficiency.The journal of allergy and clinical immunology. Global · 2024Article
39 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary immune thrombocytopenia (ITP) is a disorder caused by autoantibody-mediated platelet destruction and decreased platelet production. Rituximab, a B cell-depleting agent, has become the first-line treatment for ITP; however, patients with refractory disease usually require splenectomy. We identified antibody-secreting cells as the major splenic B cell population that is resistant to rituximab. The phenotype, antibody specificity, and gene expression profile of these cells were characterized and compared to those of antibody-secreting cells from untreated ITP spleens and from healthy tissues. Antiplatelet-specific plasma cells (PC) were detected in the spleens of patients with ITP up to 6 months after rituximab treatment, and the PC population displayed a long-lived program similar to the one of bone marrow PC, thus explaining for most of these patients the absence of response to rituximab and the response to splenectomy. When analyzed by multiplex PCR at the single-cell level, normal splenic PC showed a markedly different gene expression profile, with an intermediate signature, including genes characteristic of both long-lived PC and proliferating plasmablasts. Surprisingly, long-lived PC were not detected in untreated ITP spleens. These results suggest that the milieu generated by B cell depletion promotes the differentiation and settlement of long-lived PC in the spleen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.